NASDAQ · SPRO
Healthcare · Biotechnology
$1.22
Up+$0.01 (+0.83%)
Updated Aug 23, 2026, 3:47 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SPRO closed at $1.22 after 20 trading sessions, up 3.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.22 | $1.2462 | $1.21 | $1.22 | 359.14K |
| Aug 20, 2026 | $1.22 | $1.27 | $1.20 | $1.21 | 558.77K |
| Aug 19, 2026 | $1.20 | $1.24 | $1.192 | $1.23 | 480.18K |
| Aug 18, 2026 | $1.20 | $1.20 | $1.175 | $1.20 | 477.41K |
| Aug 17, 2026 | $1.21 | $1.24 | $1.19 | $1.19 | 299.01K |
| Aug 14, 2026 | $1.26 | $1.26 | $1.1937 | $1.23 | 744.55K |
| Aug 13, 2026 | $1.26 | $1.30 | $1.21 | $1.24 | 1.29M |
| Aug 12, 2026 | $1.24 | $1.245 | $1.185 | $1.19 | 774.55K |
| Aug 11, 2026 | $1.24 | $1.25 | $1.21 | $1.23 | 364.06K |
| Aug 10, 2026 | $1.25 | $1.276 | $1.225 | $1.23 | 351.02K |
| Aug 7, 2026 | $1.27 | $1.2795 | $1.24 | $1.26 | 459.03K |
| Aug 6, 2026 | $1.26 | $1.275 | $1.23 | $1.27 | 974.68K |
| Aug 5, 2026 | $1.25 | $1.28 | $1.21 | $1.26 | 574.91K |
| Aug 4, 2026 | $1.15 | $1.25 | $1.15 | $1.23 | 752.11K |
| Aug 3, 2026 | $1.19 | $1.22 | $1.125 | $1.15 | 1.37M |
| Jul 31, 2026 | $1.20 | $1.2138 | $1.17 | $1.17 | 824.58K |
| Jul 30, 2026 | $1.20 | $1.22 | $1.175 | $1.20 | 487.67K |
| Jul 29, 2026 | $1.20 | $1.21 | $1.16 | $1.19 | 1.06M |
| Jul 28, 2026 | $1.18 | $1.28 | $1.15 | $1.195 | 1.6M |
| Jul 27, 2026 | $1.20 | $1.2299 | $1.16 | $1.18 | 1.35M |
The latest Smart Investors Daily articles mentioning SPRO.
SPRO research
Company profile and research snapshot.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 30, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 20, 2024 | Evercore ISI Group | In-Line | — |
| Dec 2, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2024 | TD Cowen | Hold | — |
| Nov 15, 2024 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · May 13, 2026
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of $(0.25) per share from
Finnhub · May 13, 2026
New Drug Application for tebipenem HBr for complicated urinary tract infections , including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway...
SeekingAlpha · Feb 11, 2026
Spero Therapeuticsâ oral antibiotic tebipenem shows Phase 3 success and supports GSKâs NDA resubmission. Click here to read my latest analysis of SPRO stock.
GlobeNewswire Inc. · Nov 28, 2025
Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRO.
